Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks
Stock Research Monitor: GALT, KPTI, and LCI
LONDON, UK / ACCESSWIRE / July 11, 2018 / If you want a free Stock Review on MNK sign up now at www.wallstequities.com/registration. WallStEquities.com takes a look at the Generic Drugs market, which can be segmented into biosimilars, simple generic, and super generic. Based on its therapeutics applications, the generic drugs market can be classified into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others.Under monitoring this morning are four equities: Galectin Therapeutics Inc. (NASDAQ: GALT), Karyopharm Therapeutics Inc. (NASDAQ: KPTI), Lannett Co. Inc. (NYSE: LCI), and Mallinckrodt PLC (NYSE: MNK). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
Galectin Therapeutics
Norcross, Georgia-based Galectin Therapeutics Inc.'s stock finished Tuesday's session 2.24% lower at $6.56 with a total trading volume of 466,435 shares. Over the last month and the previous three months, the Company's shares have advanced 6.32% and 36.10%, respectively. Additionally, the stock has surged 174.48% over the past year. Shares of the Company are trading above their 50-day and 200-day moving averages by 21.82% and 63.39%, respectively. Moreover, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease, skin disease, and cancer, have a Relative Strength Index (RSI) of 52.16.
On June 27th, 2018, Galectin Therapeutics announced that it has received notice of issuance of USPatent Number 9,968,631titled, "Method and Treatment of Pulmonary Fibrosis." The patent's principal claims cover method of use of GR-MD-02 as a means to treat pulmonary fibrosis. The patent is expected to provide broad protection for the use of GR-MD-02 for compositions, methods of using and methods of manufacturing compositions capable of treating pulmonary fibrosis. The patent coverage extends to 2032. Get the full research report on GALT for free by clicking below at:
www.wallstequities.com/registration/?symbol=GALT
Karyopharm Therapeutics
Shares in Newton, Massachusetts headquartered Karyopharm Therapeutics Inc. declined slightly by 0.16%, ending yesterday's session at $18.63 with a total trading volume of 202,001 shares. The stock has gained 5.91% in the past month, 46.00% in the previous three months, and 96.93% over the past year. The Company's shares are trading 4.96% above their 50-day moving average and 37.59% above their 200-day moving average. Moreover, shares of Karyopharm Therapeutics, which focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases, have an RSI of 56.29.
On June 25th, 2018, Karyopharm Therapeutics announced the appointment of Anand Varadan as Executive Vice President, Chief Commercial Officer. In this role, Mr. Varadan will lead the Company's commercial strategy and operations, including for the launch of selinexor, its lead, novel, oral SINE compound. Find your free research report on KPTI at:
www.wallstequities.com/registration/?symbol=KPTI
Lannett
On Tuesday, Philadelphia, Pennsylvania-based Lannett Co. Inc.'s stock closed the day flat at $14.15. A total volume of 261,147 shares was traded. The Company's shares are trading 8.05% below their 50-day moving average. Additionally, shares of Lannett, which develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the US, have an RSI of 46.04.
On June 29th, 2018, Lannett announced a restructuring and cost reduction plan of its subsidiary, Cody Laboratories, a developer and manufacturer of pain management active pharmaceutical ingredients. The plan is expected to generate annualized cost savings of approximately$10 millionand be substantiallycompleted by December 2018.Sign up today for the free research report on LCI at:
www.wallstequities.com/registration/?symbol=LCI
Mallinckrodt
Shares in Staines-Upon-Thames, UK-based Mallinckrodt PLC ended the day 1.01% higher at $20.98. A total volume of 4.00 million shares was traded, which was above their three months average volume of 3.28 shares. The stock has gained 8.54% in the last month and 39.68% in the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 23.51% and 0.98%, respectively. Furthermore, shares of Mallinckrodt, which develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle-Eastern, African, and Asia/Pacific regions, have an RSI of 70.91.
On June 28th, 2018, Mallinckrodt announced that it has completed enrollment of its ongoing Phase-4 clinical trial of H.P. Acthar®Gel for Rheumatoid Arthritis (RA) patients. The study is assessing the efficacy and safety of H.P. Acthar Gel in RA patients with persistently active disease. Target enrollment was 230 patients, and that goal has been exceeded. Wall St. Equities' research coverage also includes the downloadable free report on MNK at:
www.wallstequities.com/registration/?symbol=MNK
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities
